Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSF-1
- Development stage
- Preclinical
- Lead developer
- OssiFi
- Modality
- Small Molecules
- Administration
- Implant
01
Overview
OSF-1 is an investigational small molecule sclerostin inhibitor being developed by OssiFi as an advanced bone graft substitute. Unlike traditional orthobiologics, OSF-1 is designed to promote localized bone formation and spinal fusion by inhibiting the Wnt-antagonizing activity of sclerostin, thereby decoupling bone formation from resorption. Delivered locally on a carrier matrix, OSF-1 is being evaluated for the treatment of degenerative disc disease, low back pain, and for facilitating spinal fusion.
02
Targets
SOST (Sclerostin)
Beyond the preview
Go deeper on OSF-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSF-1.